3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Uveal Melanoma
1
Solid Tumor
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Glioma
1
Disease Progression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
pembrolizumab
54
Nivolumab
50
Ipilimumab
28
Cyclophosphamide
16
binimetinib
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
fludarabine
9
Radiosurgery
9
relatlimab
8
encorafenib
8
Opdualag
8
Biopsy
8
aldesleukin
7
Interleukin-2
7
atezolizumab
6
Immunotherapy
6
Blood Specimen Collection
6
cemiplimab
5
CTLA-4 Antigen
5
Bevacizumab
5
trametinib
4
fludarabine phosphate
4
dabrafenib
4
Temozolomide
4
Paclitaxel
4
Immune Checkpoint Inhibitors
4
spartalizumab
3
Surgical Procedures, Operative
3
Metformin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Melanoma
×
Valproic Acid
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled